Tempus AI Extends AstraZeneca Partnership With $200 Million Five-Year Commitment
Tempus AI amended its agreement with AstraZeneca, securing a $200 million five-year commitment, with a minimum of $32 million annually. The deal extends through 2031, with a possible one-year extension if commitments aren't met. AstraZeneca must pay any shortfall if terminated early, according to the company's SEC filing.
How this was made

The 30-second read
Why it matters
The $200 million commitment is a material revenue boost, likely to be reflected in Tempus AI's near‑term valuation.
Market read
First disclosure of a sizable pharma partnership for Tempus AI, creating immediate trading interest.
What to watch
The agreement includes a penalty clause that could affect cash flow if AstraZeneca terminates early.
Background
Tempus AI provides AI‑driven clinical data platforms; AstraZeneca is a major pharma client.
Ticker impact
Tempus AI announced a $200 million five‑year partnership extension with AstraZeneca, adding a minimum $32 million annual spend.
upward pressure as investors price in the additional $200 million of committed revenue
The deal size is material for Tempus AI and represents the first public disclosure, which typically triggers a short‑term price rally.
Market effects
Strengthens the biotech data‑analytics sector by highlighting pharma partnerships.
May boost sentiment for US‑listed health‑tech stocks.
Limited to investors tracking pharma‑tech collaborations.
Counterpoint
If AstraZeneca reduces spend later, the partnership could underperform expectations.
Key entities
- companyTempus AI, Inc.
US‑listed provider of AI‑enabled clinical data solutions.
- companyAstraZeneca
Global pharmaceutical company entering a five‑year partnership.

